EPCAM and neoplasm: Solitomab, a bispecific antibody that both activates effector T cells via CD3 and targets tumor surface antigen EpCAM, was screened in a manner similar to that for Cisplatin—6-dose, serially diluted curves with a 4-day treatment duration and high-content imaging endpoints of total tumor area reduction and tumor killing.